<DOC>
	<DOCNO>NCT00986206</DOCNO>
	<brief_summary>RATIONALE : Screening test , lysophosphatidic acid assay , may help doctor find cancer cell early plan well treatment ovarian cancer . PURPOSE : This clinical trial study use lysophosphatidic acid assay see well work early detection ovarian cancer patient ovarian cancer risk ovarian cancer .</brief_summary>
	<brief_title>Lysophosphatidic Acid Assay Patients With Ovarian Cancer Who Are Risk Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To validate new assay lysophosphatidic acid ( LPA ) early detection ovarian cancer . Secondary - To estimate risk find ovarian cancer time surgery pre- post-menopausal woman present pelvic mass compare LPA result surgical patient group `` normal '' , disease-free woman high-risk ovarian cancer . Tertiary - To examine response primary adjuvant treatment recurrence disease . - To evaluate urine level CA125 LPA determine ability estimate risk cancer time surgery patient present pelvic mass . ( exploratory ) OUTLINE : Blood urine sample collect day surgery ; , , complete chemotherapy ; clinic visit . Samples test concentration CA125 lysophosphatidic acid ( LPA ) use new assay compare liquid chromatography/electrospray ionization-tandem mass spectrometry result . Remaining serum , plasma , urine store frozen future research evaluation novel biomarkers diagnosis prognosis cancer . After completion study , patient follow periodically approximately 5 year . PROJECTED ACCRUAL : A total 500 surgical patient , 100 cancer patient undergo first-line therapy , 40 disease-free woman know BRCA-mutation carrier accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets 1 follow criterion : Presenting gynecological oncologist unilateral bilateral pelvic mass ( defined simple , complex , solid ovarian/pelvic mass ) schedule undergo surgery Newly diagnose epithelial ovarian cancer undergo firstline chemotherapy History epithelial ovarian carcinoma status postprimary chemotherapy treatment , currently clinical remission accord follow criterion : Absence symptom may relate disease Imaging without abnormality â‰¥ 1 cm suspicious disease ( ascites ) CA125 obtain twice least 3 week apart increase 50 % &lt; 40 units/mL Known BRCA mutation intact ovary ( prior bilateral salpingooophorectomy ) No synchronous primary endometrial cancer past history primary endometrial cancer , unless follow condition meet : Stage great IB No superficial myometrial invasion , without vascular lymphatic invasion No poorly differentiate subtypes , include papillary serous , clear cell , FIGO grade 3 lesion No epithelial ovarian carcinoma low malignant potential ( borderline carcinoma ) Patients stage recur second chemotherapy induce remission eligible PATIENT CHARACTERISTICS : Pre postmenopausal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No invasive malignancy within past 5 year , exception nonmelanoma skin cancer No septicemia , severe infection , acute hepatitis PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior radiotherapy portion abdominal cavity pelvis No prior chemotherapy another malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>ovarian epithelial cancer</keyword>
	<keyword>BRCA1 mutation carrier</keyword>
	<keyword>BRCA2 mutation carrier</keyword>
	<keyword>stage IA ovarian epithelial cancer</keyword>
	<keyword>stage IB ovarian epithelial cancer</keyword>
	<keyword>stage IC ovarian epithelial cancer</keyword>
	<keyword>stage IIA ovarian epithelial cancer</keyword>
	<keyword>stage IIB ovarian epithelial cancer</keyword>
	<keyword>stage IIC ovarian epithelial cancer</keyword>
	<keyword>stage IIIA ovarian epithelial cancer</keyword>
	<keyword>stage IIIB ovarian epithelial cancer</keyword>
	<keyword>stage IIIC ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
</DOC>